NutraLife BioSciences, Inc. (NLBS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NutraLife BioSciences, Inc. (NLBS) trades at $0.0001 with AI Score 38/100 (Grade D). NutraLife BioSciences, Inc. specializes in the contract manufacturing and private labeling of nutraceuticals, dietary supplements, and a comprehensive range of cannabidiol (CBD) products. Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for NLBS: NLBS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NLBS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NLBS: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NutraLife BioSciences, Inc. (NLBS) Healthcare & Pipeline Overview
NutraLife BioSciences, Inc. specializes in the contract manufacturing and private labeling of nutraceuticals, dietary supplements, and a comprehensive range of CBD products. Based in Coconut Creek, Florida, the company leverages diverse distribution channels for its health-oriented offerings, targeting a growing wellness market with its specialized product lines.
What Is the Investment Thesis for NLBS?
NutraLife BioSciences, Inc. operates within the expanding nutraceutical, dietary supplement, and CBD markets, leveraging a contract manufacturing and private labeling business model. The company's diverse product portfolio, encompassing general wellness, specialized CBD items, skincare, and sanitizers, positions it to capitalize on increasing consumer demand for health-oriented products. Its distribution strategy, combining direct-to-consumer sales with private label partnerships and traditional retail, provides multiple avenues for market penetration. However, the company presents a high-risk profile, evidenced by a market capitalization of $0.00B and a significantly negative profit margin of -930.0%, indicating substantial losses relative to revenue. A gross margin of 13.3% suggests limited profitability from core sales. The extremely negative beta of -15.21 is an anomaly requiring deeper scrutiny. Trading on the OTC Other tier further implies potential challenges related to liquidity and disclosure. Future growth hinges on securing and retaining client contracts, navigating evolving regulatory landscapes for CBD, and improving operational efficiency to achieve profitability.
Based on FMP financials and quantitative analysis
NLBS Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or nano-cap entity with a very small market valuation.
- Profit Margin: -930.0%, reflecting significant operational losses relative to its revenue, highlighting profitability challenges.
- Gross Margin: 13.3%, suggesting a relatively low margin on its core product sales before operating expenses.
- Beta: -15.21, an unusually high negative beta indicating an extreme inverse correlation to broader market movements, which warrants further investigation into its underlying drivers.
- Employee Base: 12 employees, highlighting a lean operational structure for its diverse product offerings and manufacturing activities.
Who Are NLBS's Competitors?
NLBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.13 | -16.67% | $36.0M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | -3.91% | $81.5M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NLBS's Key Strengths?
- Diverse product portfolio spanning nutraceuticals, CBD, skincare, and sanitizers.
- Established contract manufacturing and private labeling capabilities.
- Multi-channel distribution strategy including direct-to-consumer and wholesale.
- Positioned in growing health and wellness markets, particularly CBD and dietary supplements.
What Are NLBS's Weaknesses?
- Significant negative profit margin (-930.0%) indicating substantial operational losses.
- Low gross margin (13.3%) suggesting limited profitability from core sales.
- Trades on the OTC Other tier, implying higher risk and potentially limited liquidity.
- Small employee base (12 employees) may limit scalability and operational capacity.
What Could Drive NLBS Stock Higher?
- **Upcoming: New Private Label Client Contracts**: Securing significant new contracts for private label manufacturing or contract production could substantially increase revenue and production volume, demonstrating market demand for NutraLife BioSciences' services.
- **Upcoming: Product Line Expansions**: The introduction of new, innovative nutraceuticals, CBD formulations, or skincare products that gain market traction could drive sales growth and expand the company's market reach.
- **Ongoing: E-commerce Channel Optimization**: Continuous improvements in the company's direct-to-consumer website and digital marketing efforts could lead to increased online sales and brand recognition, enhancing profitability by reducing reliance on intermediaries.
- **Ongoing: Regulatory Clarity for CBD Products**: Any positive developments or clearer regulatory frameworks for CBD products at the federal or state level could reduce operational uncertainty and open up new market opportunities for the company's extensive CBD portfolio.
What Are the Key Risks for NLBS?
- Financial-distress signal — its Altman Z-Score of -13.54 sits in the distress zone (elevated bankruptcy risk).
- **Ongoing: Significant Negative Profitability**: The -930.0% profit margin indicates severe operational losses, posing a substantial risk to the company's long-term viability and ability to fund future growth without external capital.
- **Potential: Regulatory Changes for CBD**: The evolving and often ambiguous regulatory environment surrounding CBD products could lead to restrictions on manufacturing, marketing, or sales, negatively impacting a significant portion of the company's business.
- **Ongoing: High Competition in Wellness Markets**: The nutraceutical, dietary supplement, and CBD markets are highly saturated with numerous competitors, making it challenging for NutraLife BioSciences to gain and maintain market share and client contracts.
- **Potential: Dependency on Client Contracts**: As a contract manufacturer and private labeler, a significant portion of revenue may depend on a few key client relationships. The loss of a major client or failure to secure new contracts could severely impact financial performance.
- **Ongoing: OTC Other Tier Risks**: Trading on the OTC Other tier exposes investors to risks such as extremely limited liquidity, lack of transparent financial reporting, and potential for price manipulation, making it a highly speculative investment.
What Are the Growth Opportunities for NLBS?
- **Expansion in the Global CBD Market**: The global cannabidiol (CBD) market is projected for substantial growth, driven by increasing consumer awareness, evolving regulatory frameworks, and expanding applications across various product categories. NutraLife BioSciences, with its comprehensive CBD portfolio including tinctures, topicals, and pet products, is well-positioned to capitalize on this trend. By strategically expanding its product lines, investing in research and development for novel CBD formulations, and broadening its distribution channels, the company can capture a larger share of this burgeoning market, which is expected to continue its upward trajectory over the next decade.
- **Growth in Private Label and Contract Manufacturing**: The demand for private label dietary supplements and wellness products continues to rise as retailers and brands seek to offer unique products without the overhead of in-house manufacturing. NutraLife BioSciences' core business as a contract manufacturer and private labeler allows it to benefit directly from this trend. By securing new client contracts, leveraging its formulation expertise, and optimizing its production capabilities, the company can scale its manufacturing operations and revenue. This business model provides a stable revenue stream and reduces direct marketing costs, making it an attractive growth avenue for the company in the competitive health and wellness sector.
- **Diversification into Skincare and Hand Sanitizers**: Beyond its primary focus on nutraceuticals and CBD, NutraLife BioSciences' foray into skincare items and hand sanitizers represents a strategic diversification into broader health and personal care markets. The skincare market is consistently growing, driven by consumer demand for anti-aging, natural, and specialized dermatological products. Similarly, the hand sanitizer market, while experiencing fluctuations, maintains a baseline demand for hygiene products. This diversification can mitigate reliance on any single product category, offering resilience against market shifts and opening up additional revenue streams by tapping into established consumer needs within these adjacent sectors.
- **E-commerce and Direct-to-Consumer (DTC) Channel Enhancement**: The company's direct-to-consumer website, nutralifebiosciences.com, offers a scalable and potentially high-margin channel for growth. Investing in digital marketing strategies, search engine optimization, and user experience enhancements can significantly increase brand visibility and customer acquisition. Expanding the e-commerce footprint allows NutraLife BioSciences to reach a wider geographic audience, reduce reliance on third-party distributors for its own branded products, and foster direct relationships with consumers. This direct engagement can provide valuable market insights and potentially improve overall profit margins by cutting out intermediary costs, positioning it for long-term digital growth.
- **Increasing Demand for General Wellness and Nutraceuticals**: The overarching societal trend towards preventative health, personal wellness, and natural remedies continues to fuel robust demand for dietary supplements and nutraceuticals. Consumers are increasingly proactive about managing their health through diet and supplementation. NutraLife BioSciences, with its core business in formulating and producing vitamins, minerals, and herbal supplements, is inherently positioned to benefit from this secular growth. By continuously innovating its product offerings, responding to emerging health trends, and maintaining high-quality manufacturing standards, the company can expand its market share within this consistently growing segment of the healthcare industry.
What Opportunities Does NLBS Have?
- Expanding global demand for dietary supplements and nutraceuticals.
- Rapid growth and increasing acceptance of the cannabidiol (CBD) market.
- Potential for securing new private label and contract manufacturing clients.
- Further development and expansion of e-commerce and direct-to-consumer sales channels.
What Threats Does NLBS Face?
- Intense competition from established players in the nutraceutical and CBD industries.
- Evolving and potentially restrictive regulatory landscape for CBD products.
- Reliance on securing and maintaining client contracts for its private label business.
- Negative market perception and limited investor interest associated with OTC Other tier stocks.
What Are NLBS's Competitive Advantages?
- **Diverse Product Portfolio**: Offers a wide range of nutraceuticals, CBD products, skincare, and sanitizers, catering to varied consumer health and wellness needs.
- **Contract Manufacturing Expertise**: Possesses the capability to formulate and produce specialized health products for other brands, establishing itself as a reliable B2B partner.
- **Established Distribution Channels**: Utilizes a multi-channel approach including direct-to-consumer, private label distributors, and traditional retail, enhancing market penetration.
- **Adaptability to Market Trends**: Demonstrated ability to pivot and expand into high-growth areas like CBD and general wellness, responding to evolving consumer demands.
What Does NLBS Do?
NutraLife BioSciences, Inc., operating with its subsidiaries, is a Florida-based enterprise established in 2010, initially known as NutraFuels, Inc. The company officially adopted its current name in March 2019, signifying its evolution and focus within the biosciences sector. Headquartered in Coconut Creek, US, NutraLife BioSciences specializes in the creation, production, and distribution of a diverse portfolio of health-oriented products. This comprehensive range includes nutraceuticals, dietary supplements, and general wellness items, catering to a broad consumer base seeking health and lifestyle enhancements. A significant component of the company's offerings is its extensive line of cannabidiol (CBD) products. This CBD portfolio is robust, featuring cannabinoid-rich hemp oil sourced from industrial hemp, tinctures designed for sublingual application, and a variety of topical solutions. These topicals, such as lotions and oils, are formulated for direct skin application, often targeting pain or inflammation relief. The CBD range further extends to specialized products like face creams, massage oils, nutraceutical sprays enhanced with CBD, and even specific products tailored for pets, demonstrating a wide application of CBD technology. Beyond its core nutraceutical and CBD lines, NutraLife BioSciences also manufactures skincare items and hand sanitizers, diversifying its presence in the personal care and hygiene markets. The company operates primarily as a contract manufacturer and private labeler, formulating and producing vitamins, minerals, and herbal supplements for other brands. This business model allows it to leverage its manufacturing capabilities for a wider market reach without direct brand development costs for every product. Customers can acquire NutraLife BioSciences' products directly from its official website, nutralifebiosciences.com, or through a network of private label distributors, other online retailers, and traditional brick-and-mortar stores, ensuring broad market accessibility. With a lean operational structure supported by 12 employees, the company maintains its focus on product development and distribution within the health and wellness industry.
What Products and Services Does NLBS Offer?
- Creates, produces, and distributes nutraceuticals and dietary supplements.
- Manufactures a comprehensive range of cannabidiol (CBD) products, including tinctures and topicals.
- Develops specialized CBD products such as face creams, massage oils, and pet-specific formulations.
- Operates as a contract manufacturer and private labeler for other brands in the nutritional supplement space.
- Produces general wellness items, skincare products, and hand sanitizers.
- Sources cannabinoid-rich hemp oil from industrial hemp for its CBD product line.
- Distributes products through its own website, private label distributors, online retailers, and brick-and-mortar stores.
How Does NLBS Make Money?
- **Contract Manufacturing**: Generates revenue by formulating and producing vitamins, minerals, herbal supplements, and other wellness products for third-party brands under contract.
- **Private Labeling**: Offers white-label solutions, allowing other companies to market NutraLife BioSciences' manufactured products under their own brand names.
- **Direct-to-Consumer Sales**: Sells its own branded products, including nutraceuticals, CBD items, and skincare, directly to consumers via its e-commerce website.
- **Wholesale Distribution**: Supplies products to a network of online retailers and traditional brick-and-mortar stores, expanding market reach through established retail channels.
What Industry Does NLBS Operate In?
NutraLife BioSciences, Inc. operates within the broader Healthcare sector, specifically positioned in the Drug Manufacturers - Specialty & Generic industry, with a strong focus on nutraceuticals, dietary supplements, and cannabidiol (CBD) products. The global dietary supplement market is experiencing robust growth, driven by increasing health consciousness, aging populations, and a rising preference for preventative healthcare. Similarly, the CBD market continues to expand rapidly as regulatory environments evolve and consumer acceptance grows for its perceived wellness benefits. NutraLife BioSciences competes by offering a diverse product range and operating as a contract manufacturer and private labeler, serving other brands. This strategy allows the company to participate in market growth without the extensive marketing and brand-building costs associated with proprietary brands. However, the industry is highly competitive, with numerous players ranging from large pharmaceutical companies with generic divisions to specialized nutraceutical and CBD manufacturers, all vying for market share and client contracts. The company's ability to differentiate through product quality, formulation expertise, and efficient manufacturing processes is critical in this dynamic landscape.
Who Are NLBS's Key Customers?
- **Private Label Distributors**: Businesses that purchase products from NutraLife BioSciences to sell under their own brand names.
- **Other Online Retailers**: E-commerce platforms that stock and sell NutraLife BioSciences' products.
- **Traditional Brick-and-Mortar Stores**: Physical retail locations that carry the company's various health and wellness products.
- **Direct Consumers**: Individuals who purchase products directly from nutralifebiosciences.com for personal use.
F-Score 4/9Financial Health
NutraLife BioSciences, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -13.54 places it in the distress zone, a signal of elevated financial risk.
How NutraLife BioSciences, Inc. Is Valued
Relative to its peer group, NLBS's quantitative score of 38/100 is below the peer average of 62/100.
NLBS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in the company's future and potential growth.
- Positive community sentiment has emerged around NutraLife's innovative product offerings, attracting interest from health-conscious consumers.
- The company is gaining traction in the wellness sector, which has seen increased demand post-pandemic as consumers prioritize health.
- Strategic partnerships with key distributors have been established, enhancing market reach and brand visibility.
Bear Case
- Concerns about competition in the wellness industry may overshadow NutraLife's growth prospects as new entrants emerge.
- Recent social sentiment analysis indicates mixed feelings, with some community members questioning the sustainability of current sales trends.
- Regulatory challenges in the health supplement sector could pose risks for NutraLife's operations and product approvals.
- Market perception remains cautious due to the volatility in consumer spending, particularly in discretionary health products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NLBS Latest News
No recent news available for NLBS.
NLBS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NLBS.
Price Targets
Wall Street price target analysis for NLBS.
NLBS MoonshotScore
What does this score mean?
The MoonshotScore rates NLBS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Edgar Ward
CEO
Edgar Ward serves as the CEO of NutraLife BioSciences, Inc., overseeing the company's strategic direction and operational execution. His leadership is pivotal in managing a lean team of 12 employees, guiding the company's efforts in the creation, production, and distribution of its diverse health-oriented product lines. Ward's professional background likely encompasses experience in the healthcare, nutraceutical, or manufacturing sectors, providing him with the necessary insights to navigate the complexities of product development, regulatory compliance, and market distribution within these specialized industries. His role requires a comprehensive understanding of both B2B contract manufacturing and direct-to-consumer market dynamics.
Track Record: Under Edgar Ward's leadership, NutraLife BioSciences, Inc. has maintained its focus on a broad portfolio of nutraceuticals, dietary supplements, and an extensive range of CBD products. A key strategic decision was the company's rebranding from NutraFuels, Inc. to NutraLife BioSciences, Inc. in March 2019, signaling a refined corporate identity. His tenure has seen the company continue to operate as a contract manufacturer and private labeler, adapting to market demands for health and wellness products while managing a small, dedicated workforce.
NLBS OTC Market Information
The 'OTC Other' tier, also known as the Pink No Information tier, represents the lowest and most speculative category of over-the-counter (OTC) markets. Unlike companies listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers such as OTCQX or OTCQB, companies on OTC Other have minimal to no public disclosure requirements. This tier is characterized by a lack of financial reporting, making it challenging for investors to access current and reliable information about the company's operations, financial health, or management. Consequently, stocks in this tier are considered highly speculative and carry significant risks due to the absence of transparency and regulatory oversight.
- OTC Tier: OTC Other
- **Lack of Transparency**: Unknown disclosure status means limited access to financial statements, operational reports, or other material information, making informed investment decisions difficult.
- **Limited Liquidity**: Trading on the OTC Other tier often results in low trading volumes and wide bid-ask spreads, making it challenging to buy or sell shares efficiently.
- **Price Volatility**: Without robust market oversight and information, stock prices can be highly speculative and subject to extreme fluctuations based on limited news or rumors.
- **Regulatory Scrutiny**: Companies on lower OTC tiers may face increased scrutiny from regulators due to the lack of transparency, potentially leading to trading halts or delisting.
- **Fraud Risk**: The absence of stringent reporting requirements can increase the potential for fraudulent activities or misleading information, posing a significant risk to investors.
- Verify any available corporate filings or press releases directly from the company or third-party sources.
- Research management's background, track record, and any past regulatory issues.
- Investigate the company's business operations, product legitimacy, and market presence through independent channels.
- Assess the current market for the company's products and services, including competition and growth potential.
- Examine any legal actions or litigations involving the company or its management.
- Understand the typical trading volume and bid-ask spread to gauge potential liquidity challenges.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- **Operational History**: Established in 2010, indicating a decade-plus of continuous operation, albeit with a name change.
- **Physical Headquarters**: Based in Coconut Creek, Florida, suggesting a tangible operational presence.
- **Public Website**: The existence of nutralifebiosciences.com provides a direct channel for product information and sales.
- **Diverse Product Portfolio**: Engages in the manufacturing and distribution of a range of health-oriented products, including nutraceuticals, CBD, skincare, and sanitizers.
- **Contract Manufacturing Model**: Operates as a contract manufacturer and private labeler, a legitimate business model within the industry.
What Investors Ask About NutraLife BioSciences, Inc. (NLBS) — Healthcare
What does the AI Score mean for NLBS?
NLBS holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. NutraLife BioSciences, Inc. specializes in the contract manufacturing and private labeling of nutraceuticals, dietary supplements, and a comprehensive range of cannabidiol (CBD) products. …
What products and services does NutraLife BioSciences, Inc. offer?
NutraLife BioSciences, Inc. specializes in the creation, production, and distribution of a diverse range of health-oriented products. This includes a comprehensive portfolio of nutraceuticals, dietary supplements, and general wellness items.
How does NutraLife BioSciences, Inc. manage regulatory compliance in the nutraceutical and CBD markets?
NutraLife BioSciences, Inc. operates within a complex regulatory landscape, particularly concerning its nutraceutical and CBD product lines. While specific details on its compliance management are not provided, companies in this sector typically adhere to regulations set by bodies such as the FDA for dietary supplements, including Good Manufacturing Practices (GMP).
What are the implications of NutraLife BioSciences, Inc. trading on the OTC Other tier?
Trading on the OTC Other tier, also known as the Pink No Information tier, carries significant implications for NutraLife BioSciences, Inc. and its investors. This tier signifies minimal to no public disclosure requirements, meaning there is an 'Unknown' status regarding the company's financial reports and operational updates.
What are the primary revenue generation strategies for NutraLife BioSciences, Inc.?
NutraLife BioSciences, Inc. employs a multi-faceted approach to revenue generation, primarily centered around its capabilities in manufacturing and distribution within the health and wellness sector. A significant portion of its revenue is derived from its role as a contract manufacturer and private labeler, where it formulates and produces nutraceuticals, dietary supplements, and other wellness products for other brands.
What are the main risks for NLBS?
NutraLife BioSciences, Inc. faces several significant risks that investors may want to evaluate. Operationally, the company exhibits a substantial negative profit margin of -930.0% and a low gross margin of 13.3%, indicating ongoing financial losses and challenges in achieving profitability from its core business.
What are the key factors to evaluate for NLBS?
NutraLife BioSciences, Inc. (NLBS) holds an AI score of 38/100 (low). Not financial advice.
How frequently does NLBS data refresh on this page?
NLBS's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NLBS's recent stock price performance?
NutraLife BioSciences, Inc. (NLBS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio spanning nutraceuticals, CBD, skincare, and sanitizers. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The beta value of -15.21 is unusually high and negative, which is atypical for most companies and may warrant further investigation beyond the scope of provided data.
- The market capitalization of $0.00B suggests a value less than $1 million, which aligns with the OTC Other tier and extremely small company size.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per instructions.